290 related articles for article (PubMed ID: 18549347)
21. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
[TBL] [Abstract][Full Text] [Related]
22. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
23. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Abdelalem Aziz Ahmed M
F1000Res; 2019; 8():2078. PubMed ID: 32431802
[No Abstract] [Full Text] [Related]
24. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
25. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
26. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Abbruzzese G; Barone P; Lopiano L; Stocchi F
Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
[TBL] [Abstract][Full Text] [Related]
27. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
[TBL] [Abstract][Full Text] [Related]
28. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
29. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
31. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
32. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
[TBL] [Abstract][Full Text] [Related]
33. Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia C; Maj R; Calabresi M; Maestroni S; Faravelli L; Curatolo L; Salvati P; Fariello RG
Neurology; 2006 Oct; 67(7 Suppl 2):S18-23. PubMed ID: 17030736
[TBL] [Abstract][Full Text] [Related]
34. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
[TBL] [Abstract][Full Text] [Related]
35. Spanish expert consensus on the use of safinamide in Parkinson's disease.
Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
Bianchi MLE; Riboldazzi G; Mauri M; Versino M
Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
[TBL] [Abstract][Full Text] [Related]
37. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese G; Kulisevsky J; Bergmans B; Gomez-Esteban JC; Kägi G; Raw J; Stefani A; Warnecke T; Jost WH;
J Parkinsons Dis; 2021; 11(1):187-198. PubMed ID: 33104040
[TBL] [Abstract][Full Text] [Related]
38. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Cattaneo C; Kulisevsky J; Tubazio V; Castellani P
Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008
[TBL] [Abstract][Full Text] [Related]
39. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C
J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
